Stryker Corporation vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 76)
Stryker Corporation logo

Stryker Corporation

LeaderHealthcare Tech

Enterprise

Stryker (SYK) reported $22.6B revenue in FY2024, up 11% YoY. Top-3 global medical device company. Leader in surgical robotics (Mako), implants, and emergency equipment. HQ: Kalamazoo, MI.

AI VisibilityBeta
Overall Score
B76
Category Rank
#75 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
70
Gemini
71

About

Stryker Corporation is one of the world's largest medical technology companies, headquartered in Kalamazoo, Michigan. Founded in 1941 by Dr. Homer Stryker as an orthopedic device company, Stryker has expanded through innovation and acquisitions into a comprehensive medical device platform. The company reported revenues of $22.6B in FY2024, up 11% year-over-year, with a market capitalization of approximately $135B.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

76
Overall Score
90
#75
Category Rank
#2
73
AI Consensus
83
stable
Trend
stable
74
ChatGPT
92
70
Perplexity
93
71
Gemini
89
81
Claude
96
76
Grok
95

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.